|Print Page | Close Window|
2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.View our latest Annual Report
See stock & dividend information
Baxter International Inc.
NYSE: BAXApr 26, 2018 - 1:00 PM ET
11/01/2018 7:30 AM CT
07/26/2018 7:30 AM CT
05/08/2018 9:00 AM CT
Baxter Reports First-Quarter 2018 Results and Increases Financial Outlook for Full-Year 2018
Investor relations contact
Analysts, portfolio managers, and current and prospective shareholders seeking additional investor information can contact Clare Trachtman at +1 (224) 948-3085.
Retail shareholder inquires may directed to Baxter Investor Relations at Global_CORP_Investor_Relations@baxter.com.Sign up for email alerts